Patient's Clinical Presentation and CPPopt Availability: Any Association?


Type
Article
Change log
Authors
Liberti, Annalisa 
Beqiri, Erta 
Cabeleira, Manuel 
Tas, Jeanette 
Abstract

BACKGROUND: The 'optimal' CPP (CPPopt) concept is based on the vascular pressure reactivity index (PRx). The feasibility and effectiveness of CPPopt guided therapy in severe traumatic brain injury (TBI) patients is currently being investigated prospectively in the COGiTATE trial. At the moment there is no clear evidence that certain admission and treatment characteristics are associated with CPPopt availability (yield). OBJECTIVE: To test the relation between patients' admission and treatment characteristics and the average CPPopt yield. METHODS: Retrospective analysis of 230 patients from the CENTER-TBI high-resolution database with intracranial pressure (ICP) measured using an intraparenchymal probe. CPPopt was calculated using the algorithm set for the COGiTATE study. CPPopt yield was defined as the percentage of CPP monitored time (%) when CPPopt is available. The variables in the statistical model included age, admission Glasgow Coma Scale (GCS), gender, pupil response, hypoxia and hypotension at the scene, Marshall computed tomography (CT) score, decompressive craniectomy, injury severity score score and 24-h therapeutic intensity level (TIL) score. RESULTS: The median CPPopt yield was 80.7% (interquartile range 70.9-87.4%). None of the selected variables showed a significant statistical correlation with the CPPopt yield. CONCLUSION: In this retrospective multicenter study, none of the selected admission and treatment variables were related to the CPPopt yield.

Description
Keywords
Cerebral autoregulation, ICP monitoring, Optimal CPP, TBI, Brain Injuries, Traumatic, Cerebrovascular Circulation, Glasgow Coma Scale, Humans, Intracranial Pressure, Retrospective Studies
Journal Title
Acta Neurochir Suppl
Conference Name
Journal ISSN
0065-1419
2197-8395
Volume Title
131
Publisher
Springer International Publishing
Rights
All rights reserved
Sponsorship
European Commission (602150)